Computational Design of Copper Ligands with Controlled Metal Chelating, Pharmacokinetics, and Redox Properties for Alzheimer's Disease
- PMID: 34032611
- DOI: 10.3233/JAD-200911
Computational Design of Copper Ligands with Controlled Metal Chelating, Pharmacokinetics, and Redox Properties for Alzheimer's Disease
Abstract
Background: Redox active metal cations, such as Cu2 +, have been related to induce amyloid plaques formation and oxidative stress, which are two of the key events in the development of Alzheimer's disease (AD) and others metal promoted neurodegenerative diseases. In these oxidative events, standard reduction potential (SRP) is an important property especially relevant in the reactive oxygen species formation.
Objective: The SRP is not usually considered for the selection of drug candidates in anti-AD treatments. In this work, we present a computational protocol for the selection of multifunctional ligands with suitable metal chelating, pharmacokinetics, and redox properties.
Methods: The filtering process is based on quantum chemical calculations and the use of in silico tools. Calculations of SRP were performed by using the M06-2X density functional and the isodesmic approach. Then, a virtual screening technique (VS) was used for similar structure search.
Results: Protocol application allowed the assessment of chelating, drug likeness, and redox properties of copper ligands. Those molecules showing the best features were selected as molecular scaffolds for a VS procedure in order to obtain related compounds. After applying this process, we present a list of candidates with suitable properties to prevent the redox reactions mediated by copper(II) ion.
Conclusion: The protocol incorporates SRP in the filtering stage and can be effectively used to obtain a set of potential drug candidates for AD treatments.
Keywords: Alzheimer’s disease; antioxidants; computer-aided drug design; density functional theory (DFT) calculations; drug discovery; metal complexes; redox.
Similar articles
-
Computational Evaluation of the Potential Pharmacological Activity of Salen-Type Ligands in Alzheimer's Disease.J Alzheimers Dis. 2024;99(s2):S383-S396. doi: 10.3233/JAD-230542. J Alzheimers Dis. 2024. PMID: 37483007
-
Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.J Am Chem Soc. 2009 Feb 4;131(4):1436-51. doi: 10.1021/ja806062g. J Am Chem Soc. 2009. PMID: 19133767
-
Metal Ions in Alzheimer's Disease: A Key Role or Not?Acc Chem Res. 2019 Jul 16;52(7):2026-2035. doi: 10.1021/acs.accounts.9b00248. Epub 2019 Jul 5. Acc Chem Res. 2019. PMID: 31274278
-
Management of oxidative stress and other pathologies in Alzheimer's disease.Arch Toxicol. 2019 Sep;93(9):2491-2513. doi: 10.1007/s00204-019-02538-y. Epub 2019 Aug 22. Arch Toxicol. 2019. PMID: 31440798 Review.
-
Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer's Disease.Int J Mol Sci. 2021 Jul 19;22(14):7697. doi: 10.3390/ijms22147697. Int J Mol Sci. 2021. PMID: 34299316 Free PMC article. Review.
Cited by
-
Role of Metal Cations of Copper, Iron, and Aluminum and Multifunctional Ligands in Alzheimer's Disease: Experimental and Computational Insights.ACS Omega. 2023 Jan 25;8(5):4508-4526. doi: 10.1021/acsomega.2c06939. eCollection 2023 Feb 7. ACS Omega. 2023. PMID: 36777601 Free PMC article. Review.
-
Computational evaluation of the oxidation of superoxide to molecular dioxygen mediated by NNNN-tetradentate copper complexes.RSC Adv. 2024 Dec 2;14(51):38153-38161. doi: 10.1039/d4ra07126c. eCollection 2024 Nov 25. RSC Adv. 2024. PMID: 39624430 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical